254 related articles for article (PubMed ID: 11440661)
1. [Antifungal susceptibility of emerging yeast pathogens].
García-Martos P; Domínguez I; Marín P; García-Agudo R; Aoufi S; Mira J
Enferm Infecc Microbiol Clin; 2001; 19(6):249-56. PubMed ID: 11440661
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp.
Barchiesi F; Tortorano AM; Di Francesco LF; Cogliati M; Scalise G; Viviani MA
J Antimicrob Chemother; 1999 Feb; 43(2):295-9. PubMed ID: 11252339
[TBL] [Abstract][Full Text] [Related]
4. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA
J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817
[TBL] [Abstract][Full Text] [Related]
5. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
7. [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds].
Manzano-Gayosso P; Méndez-Tovar LJ; Arenas R; Hernández-Hernández F; Millán-Chiu B; Torres-Rodríguez JM; Cortés-González E; Fernández R; López-Martínez R
Rev Iberoam Micol; 2011; 28(1):32-5. PubMed ID: 21147249
[TBL] [Abstract][Full Text] [Related]
8. A comparison of susceptibility to five antifungal agents of yeast cultures from burn patients.
Still JM; Law EJ; Belcher KE; Spencer SA
Burns; 1995 May; 21(3):167-70. PubMed ID: 7794495
[TBL] [Abstract][Full Text] [Related]
9. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
10. Yeasts and fluconazole susceptibility in the Philippines.
Bulmer GS; Marquez ML; Co-Barcelona L; Fromtling RA
Mycopathologia; 1999; 146(3):117-20. PubMed ID: 10823182
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.
Nenoff P; Oswald U; Haustein UF
Mycoses; 1999; 42(11-12):629-39. PubMed ID: 10680439
[TBL] [Abstract][Full Text] [Related]
12. Yeasts from Scarlet ibises (Eudocimus ruber): A focus on monitoring the antifungal susceptibility of Candida famata and closely related species.
Brilhante RSN; Silva ALD; Monteiro FOB; Guedes GMM; Sales JA; Oliveira JS; Maia Junior JE; Miranda SA; Sidrim JJC; Alencar LP; Castelo-Branco DSCM; Cordeiro RA; Pereira Neto WA; Rocha MFG
Med Mycol; 2017 Oct; 55(7):725-732. PubMed ID: 28204651
[TBL] [Abstract][Full Text] [Related]
13. Drug susceptibility of 64 strains of Rhodotorula sp.
Krzyściak P; Macura AB
Wiad Parazytol; 2010; 56(2):167-70. PubMed ID: 20707302
[TBL] [Abstract][Full Text] [Related]
14. Experimental evaluation of antifungal and antiseptic agents against Rhodotorula spp.
Preney L; Théraud M; Guiguen C; Gangneux JP
Mycoses; 2003 Dec; 46(11-12):492-5. PubMed ID: 14641623
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of clinical isolates of yeasts to anti-fungal agents.
Hussain Qadri SM; Flournoy DJ; Qadri SG; Ramirez EG
Mycopathologia; 1986 Sep; 95(3):183-7. PubMed ID: 3773980
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the isolation of Candida species from hospitalized patients.
Magalhães YC; Bomfim MR; Melônio LC; Ribeiro PC; Cosme LM; Rhoden CR; Marques SG
Braz J Microbiol; 2015 Mar; 46(1):117-23. PubMed ID: 26221096
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ; Jones RN
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):101-5. PubMed ID: 14972378
[TBL] [Abstract][Full Text] [Related]
18. Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species.
Melhem MS; Bertoletti A; Lucca HR; Silva RB; Meneghin FA; Szeszs MW
Braz J Microbiol; 2013 Dec; 44(4):1257-66. PubMed ID: 24688520
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibility of emerging opportunistic yeasts and yeast-like fungi from Rhea americana.
de Aguiar Cordeiro R; Pereira de Alencar L; Nogueira Brilhante RS; de Souza Collares Maia Castelo-Branco D; Cordeiro Teixeira CE; de Brito Macedo R; Teixeira Lima D; Paiva de Araújo Neto M; Jalles Monteiro A; Dutra Alves N; Franco de Oliveira M; Costa Sidrim JJ; Rocha Gadelha MF
Can J Microbiol; 2013 Aug; 59(8):577-80. PubMed ID: 23899001
[TBL] [Abstract][Full Text] [Related]
20. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
